Relaxera and CBL Patras Announce Exclusive Agreement on Manufacturing and Sales of Synthetic Human Relaxin-2
BENSHEIM, Germany and PATRAS, Greece, December 16, 2020 / B3C newswire / --Relaxera Pharmazeutische Gesellschaft mbH & Co. KG and CBL Patras (Chemical and Biopharmaceutical Laboratories) announce the signing of an exclusive contract for human relaxin-2. This cooperation agreement designates CBL as the exclusive manufacturing partner for synthetic human relaxin-2 (GMP and non-GMP) and Relaxera as the exclusive sales executive partner for relaxin. Relaxera currently undertakes research to characterize synthetic human relaxin-2 as a pharmaceutical candidate for HFpEF (Heart Failure with preserve...
Source: b3cnewswire.com
